British Journal of Clinical Pharmacology

Article	Citations
	75
Issue Information	68
Issue Highlights	65
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	58
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	56
Pregabalin poisoning: Evaluation of dose‐toxicity relationship	55
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	55
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	54
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	53
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	51
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	43
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	42
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	41
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	41
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	40
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	40
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	38
Triple antithrombotic therapy and dual therapy – What is the evidence base?	38
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	36
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	35
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	35
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	34
Antidepressants are not safe during pregnancy and in women of child‐bearing age	34
Modelling the progression of illicit substance use patterns from real‐world evidence	33
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	32

Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	32
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	30
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	30
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	30
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	30
Potential drug–drug interactions when managing status epilepticus patients in intensive care: A cohort study	29
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	29
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	29
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	28
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	28
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	28
	27
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	27
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	27
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database	27
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	26
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	25
Selected Abstracts from Pharmacology 2024	24
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	24
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	24
Lemborexant levels in breast milk after single doses in healthy, lactating women	23
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	23
Comparison of a polypharmacy‐based scale with Charlson comorbidity index to predict 6‐month mortality in chronic complex patients after an ED visit	23
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	22
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	22
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	22
	22
Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study	22
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	22
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	22
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	22
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper	21
The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	21
Issue Information	21
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	21
Issue Highlights	21
Medication compliance aids unpackaged: A national survey	21
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	21
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	20
Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?	20
A pharmacometrics model to define docetaxel target in early breast cancer	20
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	20
In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database	20
Validation of self‐reported medication use applying untargeted mass spectrometry‐based metabolomics techniques in the Rhineland study	20
The trajectory of pharmacometrics to support drug licensing and labelling	20
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	20
Coping with COVID: Preparing prescribers during the pandemic	20
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	20
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	19
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	19

Performance of the ChatGPT large language model for decision support in community pharmacy	19
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	19
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	19
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	18
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	18
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing	18
Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods	18
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	18
Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	18
The impact of a preprescribing formative assessment on learning in final‐year medical students using hospital inpatient electronic prescribing systems	18
Management of serotonin syndrome (toxicity)	18
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	17
Spotlight commentary: Innovations in clinical trials	17
Correction	17
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	17
	17
	17
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	17
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	17
Sustainable medicines use in clinical practice: A clinical pharmacological view on eco‐pharmaco‐stewardship	17
Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study	17
Epigenetic modifications in drug‐induced liver injury: A systematic review	17
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	17
Issue highlights	17
Do we become better prescribers after graduation: A 1‐year international follow‐up study among junior doctors	17
Issue Highlights	17
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	16
Challenging times: Delivering gene therapies and an opportunity for shared learning	16
Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis‐inspired systematic review	16
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	16
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	16
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	16
Association of renin–angiotensin–aldosterone system inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK biobank	16
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	16
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	16
Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials	16
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	16
Ethical concern regarding the UK PANORAMIC COVID‐19 trial	16
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	16
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	16
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	15
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	15
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	15
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	15
Physostigmine should be used more readily for antimuscarinic toxicity: CON	15
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	15
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model	15
Issue Information	15
Issue Highlights	15
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	15
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	15
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	15
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	14
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children	14
Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis	14
Student perspectives on AI‐supported formative assessment in pharmacology	14
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	14
Assessment and evaluation of prescribing competences: A systematic review and recommendations	14
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	14
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	14
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	14
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	14
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	14
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	13
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	13
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	13
	13
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam	13
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study	13
Risk of out‐of‐hospital cardiac arrest in antidepressant drug users	13
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	13
Appraising the visibility, relevance and impacts of clinical pharmacology	13
Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma	13
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?	13
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	13
Issue Information	13
Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	13
Paediatric and obstetrical pharmacology – Pushing the frontier forward	12
Issue Information	12
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	12

Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	12
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	12
Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research	12
Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy	12
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	12
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	12
Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation	12
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	12
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	12
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	12
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	12
Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs	12
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	12
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	12
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation	12
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	12
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	12
Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	12
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	12
Results of the first international quality control programme for oral targeted oncolytics	12
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	12
Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Issue Information	12
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	12
Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review	12
Pro: Oximes should be used routinely in organophosphate poisoning	12
Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data	11
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	11
Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women	11
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	11
Spotlight commentary: New Frontiers in pneumonia treatment	11
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer	11
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	11
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	11
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	11
Issue Information	11
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	11
	11
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	11
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	11
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	11
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
Assessment of the influence of body fat indices on antihypertensive drug responses	11
Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis	11
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	11
Issue Information	11
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals	11
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols	11
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers	11
External validation of a therapeutic window for risperidone in children with autism spectrum disorder	10
Drug shortages. Part 1. Definitions and harms	10
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial	10
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib	10
Safe and supportive prescribing in transgender and non‐binary patients with cancer	10
Concentrations of psychoactive substances in blood samples from non‐fatal and fatal opioid overdoses	10
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	10
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	10
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	10
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report	10
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	10
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	10
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	10
Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis	10
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	10
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	10
Clinical validation of clinical decision support systems for medication review: A scoping review	10
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	10
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma	10
Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective	10
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	10
Clinical pharmacology in adolescent transgender medicine	10
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	10
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	10
Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4‐methylaminoantipyrine	10
Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus	10
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	10
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	9
Twice neglected? Neglected diseases in neglected populations	9
Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care	9
Population pharmacokinetic analysis of doravirine in real‐world people with HIV	9
Call to action: Harmonization of pharmacovigilance regulations for post‐marketing pregnancy and breastfeeding safety studies	9
Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients	9
Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database	9
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	9
Anthony Peck (1933–2021)	9
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation	9
Revisiting the inter‐rater reliability of drug treatment assessments according to the STOPP/START criteria	9
Question‐based development of high‐risk medical devices: A proposal for a structured design and review process	9
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen	9
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects	9
Economic evaluations of therapeutic drug monitoring interventions in acute hospital‐based settings: A systematic review	9
Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens	9
Cardiovascular protection conferred by glucagon‐like peptide‐1 receptor agonists: A role for serum uric acid reduction?	9